Compare SRRK & EXPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | EXPO |
|---|---|---|
| Founded | 2012 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.7B |
| IPO Year | 2018 | 1990 |
| Metric | SRRK | EXPO |
|---|---|---|
| Price | $47.62 | $79.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | $51.20 | ★ $90.50 |
| AVG Volume (30 Days) | ★ 1.0M | 352.5K |
| Earning Date | 02-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $582,014,000.00 |
| Revenue This Year | N/A | $5.35 |
| Revenue Next Year | $20,029.43 | $10.24 |
| P/E Ratio | ★ N/A | $34.22 |
| Revenue Growth | N/A | ★ 12.25 |
| 52 Week Low | $22.71 | $63.81 |
| 52 Week High | $49.82 | $97.57 |
| Indicator | SRRK | EXPO |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 57.34 |
| Support Level | $44.10 | $69.00 |
| Resistance Level | $49.82 | $74.07 |
| Average True Range (ATR) | 2.35 | 2.33 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 45.47 | 81.78 |
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.